

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 May 2001 (03.05.2001)

PCT

(10) International Publication Number
WO 01/31028 A2

(51) International Patent Classification⁷: **C12N 15/53**,
9/02, C12Q 1/66

SP4 0JQ (GB). **WILLEY, Tara, Louise** [GB/GB]; The Babraham Institute, Babraham Hall, Village of Babraham, Cambridge CB2 4AT (GB).

(21) International Application Number: PCT/GB00/04133

(22) International Filing Date: 26 October 2000 (26.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9925161.3 26 October 1999 (26.10.1999) GB
0016744.5 10 July 2000 (10.07.2000) GB

(74) Agent: **BOWDERY, A., O.**; D/IPR, Formalities Section, Poplar 2, MOD Abbey Wood #19, Bristol BS34 8JH (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SQUIRRELL, David, James** [GB/GB]; CBD Porton Down, Salisbury, Wiltshire SP4 0JQ (GB). **MURPHY, Melenie, Jane** [GB/GB]; CBD Porton Down, Salisbury, Wiltshire SP4 0JQ (GB). **PRICE, Rachel, Louise** [GB/GB]; CBD Porton Down, Salisbury, Wiltshire SP4 0JQ (GB). **WHITE, Peter, John** [GB/GB]; CBD Porton Down, Salisbury, Wiltshire

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL ENZYME

(57) **Abstract:** A recombinant protein having luciferase activity and at least 60 % similarity to a wild-type luciferase wherein in the sequence of the enzyme, the amino acid residue corresponding to residue 357 in *Photinus pyralis* luciferase is mutated as compared to the corresponding wild-type luciferase, such that the luciferase enzyme is able to emit light at a different wavelength as compared to the corresponding wild-type luciferase and/or has enhanced thermostability as compared to the corresponding wild-type luciferase. In general, the residue corresponding to 357 in *Photinus pyralis* luciferase is changed from an acidic amino acid to a non-acidic amino acid and preferably an uncharged polar amino acid such as tyrosine. Mutant luciferases in accordance with the invention can produce a large (50nm) wavelength shift in emitted light and have good thermostability. The resultant colour shift can be reversed by addition of coenzyme A. These properties make the mutant particularly useful in a variety of assays.



WO 01/31028 A2

Novel Enzyme

The present invention relates to a novel protein, in particular mutant luciferase enzymes which show distinctive properties as compared to corresponding wild type enzyme, to DNA encoding these proteins, to the use of these enzyme in assays and to test kits containing them.

Firefly luciferase catalyses the oxidation of luciferin in the presence of ATP, Mg^{2+} and molecular oxygen with the resultant production of light. This reaction has a quantum yield of about 0.88. The light emitting property has led to its use in a wide variety of luminometric assays where ATP levels are being measured. Examples of such assays include those which are based upon the described in EP-B-680515 and WO 96/02665 but many others are used routinely in laboratories.

Luciferase is obtainable directly from the bodies of insects, in particular beetles such as fireflies or glow-worms. Particular species from which luciferases have been obtained include the Japanese GENJI or KEIKE fireflies, *Luciola cruciata* and *Luciola lateralis*, the East European firefly *Luciola mingrellica*, the North American firefly *Photinus pyralis* and the glow-worm *Lampyrus noctiluca*.

However, since many of the genes encoding these enzymes have been cloned and sequenced, they may also be produced using recombinant DNA technology. Recombinant DNA sequences encoding the enzymes are used to transform microorganisms such as *E. coli* which then express the desired enzyme product.

The colour of the light emitted by these enzymes when used in assays in the laboratory are broadly similar. It would be helpful if the wavelength could be altered, either to be more easily read by the specific detector, or for use in systems where multiple reporters are required, for example to monitor different events within the same sample. One way of distinguishing reporter molecules is to utilise luciferase

molecules which emit light at distinct wavelengths. This may be achieved by using reporter molecules comprising luciferases derived from different species of beetle or glow-worm. An alternative strategy however is to produce mutant luciferases using recombinant DNA technology, so as to produce a variation in the wavelength of the signal. Examples of such mutants are provided in WO 95/18853.

Furthermore, the heat stability of wild and recombinant type luciferases is such that they lose activity quite rapidly when exposed to temperatures in excess of about 30°C, particularly over 35°C. This instability causes problems when the enzyme is used or stored at high ambient temperature, or if the assay is effected under high temperature reaction conditions, for example in order to increase reaction rate.

Mutant luciferases having increased thermostability are known from EP-A-524448 and WO/95/25798. The first of these describes a mutant luciferase having a mutation at position 217 in the Japanese firefly luciferase, in particular by replacing a threonine residue with an isoleucine residue. The latter describes mutant luciferases having over 60% similarity to luciferase from *Photinus pyralis*, *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis* but in which the amino acid residue corresponding to residue 354 of *Photinus pyralis* or 356 of the *Luciola* species is mutated such that it is other than glutamate, and in particular is other than glutamate, aspartate, proline or glycine.

Co-pending British Patent Application No.9823468.5 and the International Patent Application derived from it, describes further such mutants. In this case, proteins are described which have luciferase activity and at least 60% similarity to wild-type luciferase such as those from *Photinus pyralis*, *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis* enzyme, but which include mutations at various positions in the protein, including amongst others, (a) the amino acid residue

corresponding to residue 214 in *Photinus pyralis* luciferase and to residue 216 of *Luciola mingrellica*, *Luciola cruciata* or *Luciola lateralis* luciferase; or

(b) the amino acid residue corresponding to residue 232 in
5 *Photinus pyralis* luciferase and to residue 234 of *Luciola mingrellica*, *Luciola cruciata* or *Luciola lateralis* luciferase; or

(c) amino acid residue corresponding to residue 295 in *Photinus pyralis* luciferase and to residue 297 of *Luciola mingrellica*,
10 *Luciola cruciata* or *Luciola lateralis* luciferase.

The applicants have found that by mutating (or introducing) an amino acid at a different position within the luciferase protein, large shifts in the wavelength of the emitted light
15 may be achieved and/or the enzyme has improved thermostability. Furthermore, the proton flux of emitted light may be improved, making the enzyme better suited to *in vivo* assays where glow kinetics are precluded or *in vitro* assays where CoA or other 'glow kinetic inducing' compounds are not present.

20

The present invention provides a recombinant protein having luciferase activity and at least 60% similarity to a wild-type luciferase wherein in the sequence of the enzyme, the amino acid residue corresponding to residue 357 in *Photinus pyralis*
25 luciferase is mutated as compared to the corresponding wild-type luciferase, such that the luciferase enzyme is able to emit light at a different wavelength as compared to the corresponding wild-type luciferase and/or has enhanced thermostability as compared to the corresponding wild-type
30 luciferase.

Wild-type luciferase sequences which can form the basis of the recombinant forms of the invention include *Photinus pyralis*, *Luciola mingrellica*, *Luciola cruciata* or *Luciola lateralis*,
35 *Hotaria paroula*, *Pyrophorus plagiophthalmus* *Lampyris noctiluca*, *Pyrocoelia nayako*, *Photinus pennsylvanica* or

Phrixothrix (railroad-worms - see Biochem. 38 (1999) 8271-8279).

Bioluminescent enzymes from species that can use the substrate D-luciferin (4,5-dihydro-2-[6-hydroxy-2-benzothiazolyl]-4-thiazole carboxylic acid) to produce light emission may form the basis of the mutant enzymes of the invention.

Particular wild-type luciferase sequences which can form the basis of the recombinant forms of the invention include

10 *Photinus pyralis*, *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis*, *Hotaria paroula*, *Pyrophorus plagiophthalmus*, *Lampyrus noctiluca*, *Pyrocoelia nayako* and *Photinus pennsylvanica*.

15 In particular, the luciferases are enzymes obtainable from *Photinus pyralis*, *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis* enzyme. In *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis* enzymes, the appropriate amino acid residue is at position 359 in the sequence.

20

The sequences of all the various luciferases show that they are highly conserved having a significant degree of similarity between them. This means that corresponding regions among the enzyme sequences are readily determinable by examination of the

25 sequences to detect the most similar regions, although if necessary commercially available software (e.g. "Bestfit" from the University of Wisconsin Genetics Computer Group; see Devereux et al (1984) Nucleic Acid Research 12: 387-395) can be used in order to determine corresponding regions or particular

30 amino acids between the various sequences. Alternatively or additionally, corresponding acids can be determined by reference to L. Ye et al., Biochim. Biophys Acta 1339 (1997) 39-52 which shows the sequences of the enzymes, together with the numbering, which numbering system is to be used in

35 connection with the present application.

As regards the possible change of the amino acid residue corresponding to residue 357 in *Photinus pyralis* luciferase, most wild-type sequences have an acid residue (aspartic acid or glutamic acid) at this position. The exception to this is some forms of the luciferase of *Photinus pennsylvanica* in which the corresponding residue (355) is the non-polar residue, valine or some forms of *Phrixothrix* luciferase where the corresponding position is V354 in Pv_{GR} or in Ph_{RE}, where it is L354 leucine. Thus in general, the amino acid used as a substitute amino acid at this position is other than aspartic acid, glutamic acid, valine or leucine.

In most cases, therefore, an acidic amino acid residue is replaced with a non-acidic residue, including basic amino acids such as lysine or arginine, non-polar amino acids such as leucine, valine or isoleucine, uncharged polar amino acids such as tyrosine, asparagine, glutamine, phenylalanine, serine, tryptophan or threonine. In particular, it may be replaced with an uncharged polar amino acid such as tyrosine, asparagine, serine or threonine. Particularly preferred amino acid residues for substitution at this position are tyrosine, phenylalanine or tryptophan and most preferably tyrosine. Generally speaking, aromatic residues at this position give rise to the largest shifts and may also assist thermostability.

Where wild-type sequences include non-acidic amino acid residues at this position, they are suitably mutated into different non-acidic residues.

It has been found that by mutating the enzyme in this way, the wavelength of light emitted by the luciferase is shifted, in some cases up to 50nm towards the red end of the spectrum. Thus, D357Y mutant *Photinus pyralis* luciferase emits light at a wavelength of some 612nm as compared to the wild-type enzyme which emits light at a wavelength of 562nm.

A wavelength shift of 50nm has considerable potential for use in assay applications as a shift of this magnitude can be

readily defined spectrally. Different coloured luciferases could be employed as reporter molecules in gene expression studies, enabling the simultaneous monitoring of more than one gene, for example as described in WO 95/18853. Multiple
5 analyte testing could also be performed with luciferase as labels.

The fact that the light in this case is a deep red in colour is particularly useful in assay methodology. A red mutant could
10 be useful when analysing a solution for ATP which contained pigments or other compounds which may absorb shorter wavelengths of light. For example, a red coloured solution would not absorb red light. Examples of red coloured solutions which are frequently the subject of such analysis include blood
15 samples or a solution of eukaryotic cell culture medium which may contain a red coloured pH indicator.

When using a mixture of colourimetric agents such as luciferases, the ability to generate a deep red signal may be
20 helpful, particularly where another agent in the sample generates a green signal. A photomultiplier tube used in photocathode spectral analysis can be set to detect either one or both peaks generated in a single sample. In other words, it is possible to distinguish between photon flux from a red and
25 green emitter in the same sample.

Furthermore, it has been found that the wavelength shift can be affected by the presence of the cofactor coenzyme A (CoA). This feature gives rise to the possibility that this enzyme
30 could be used in an assay for the cofactor.

As described below, the effect the cofactor coenzyme A on the in vitro spectrum of emitted light was investigated. As the concentration of coenzyme A increases the spectral distribution
35 alters and at the highest concentrations of CoA the spectrum is dominated by wavelengths in the region 590-630nm with a pronounced peak at 610nm.

Thus in accordance with a further aspect of the invention, there is provided an assay for determining the presence in a sample of CoA, which assay comprises adding to a sample suspected of containing CoA, luciferase as described above
5 together with other reagents which are required to bring about a luciferase/luciferin reaction, measuring the wavelength of light emitted from the sample and relating this to the presence or absence of CoA.

10 Such an assay may be useful in the detection of the state of growth or activity of cells, for example microorganisms or eukaryotic cells.

For example, the concentration of CoA in *E. coli* cells is
15 relatively high, and varies considerably with metabolic status. The mutant enzymes of the invention can be used to monitor the metabolic status of an organism, particularly the *in vivo* concentration of the CoA, since the wavelength of the emission varies depending upon the CoA concentration. Such assays may
20 be particularly useful in situations where CoA is an important primary metabolite in the production of antibiotics (e.g. in streptomycetes). Cellular CoA concentrations are also an important indicator of fatty acid biosynthesis and vary with the starvation status of the cell. A number of metabolic
25 disorders such as carcinogenesis and diabetes, show abnormalities in the fatty acid metabolites and consequently unusual CoA levels. Assays of the invention may be used in the diagnosis of such conditions. For example, the CoA levels from within a cell sample, such as a blood sample, from a patient,
30 may be determined by measuring the wavelength of light emitted from a luciferase of the invention, used in the assay. This result may be compared with that obtained from a sample of healthy cells to determine whether the wavelength has changed and thus that a modified CoA level is present. This may be
35 indicative of a disease state in the patient. Cells are suitably lysed prior to assay using a known lytic agent.

It is believed that the amino acid residue at position 357 is critically associated with the binding site of coenzyme A. When the surface of the luciferase enzyme was contoured (using SYBL protein modelling software, Tripos Ltd.) to a resolution of 1 Angstrom (\AA), a small polar pocket was noted. This pocket appears to be lined by residues H310, E354 and D357 and measured between 8-10 \AA . When viewed from the top of the molecule, this pocket appears as part of a larger pocket, lined by residues H310, E354, D357 and I232. Residues H310 and E354 appear to form a bridge across the cleft giving the appearance of two smaller pockets (See Figure 8).

Without being bound by theory, it seems possible that the bridging residues may be flexible enough to disengage when the enzyme is in solution to provide a larger pocket (~12 \AA deep and ~8 \AA wide) which allows CoA binding. This is consistent with the energy calculations.

When *E. coli* cells expressing mutants of firefly luciferase of the invention were grown on different carbon sources changes in the *in vivo* spectrum of emitted light were observed. Switching from a rich medium (LB) to a defined minimal medium with either acetate or glucose as the sole carbon source resulted in shifts to longer wavelengths of emitted light and a reduction in the contribution from shorter wavelengths. This may provide yet a further means of controlling the wavelength of light emitted for assay purposes.

Mutation of the 357 position of in the protein has been found to result in enhanced thermostability.

The proteins may contain further mutations in the sequence provided the luciferase activity of the protein is not unduly compromised. The mutations suitably enhance the properties of the enzyme or better suit it for the intended purpose in some way. This may mean that they result in enhanced thermostability and/or colour shift properties, and/or the K_m for ATP of the enzymes. Examples of mutations which give rise

to colour shifts are described in WO95/18853. Mutations which affect K_m values are described for example in WO 96/22376 and International Patent Application No. PCT/GB98/01026.

- 5 In general, effects of mutations have been found to be additive in terms of alterations in the properties.

The mutant luciferases of the invention may include other specific mutations which enhance thermostability as compared to
10 wild-type luciferase. In particular, at least one of
(a) the amino acid residue corresponding to amino acid 354 of the *Photinus pyralis* luciferase (356 in *Luciola* luciferase) is mutated;
(b) the amino acid residue corresponding to position 215 in
15 *Photinus pyralis* luciferase or (217 in *Luciola* luciferase) is a different hydrophobic amino acid; or
(c) the amino acid residue corresponding to residue 214 in *Photinus pyralis* luciferase or to residue 216 of *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis* luciferase;
20 (d) the amino acid residue corresponding to residue 232 in *Photinus pyralis* luciferase or to residue 234 of *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis* luciferase;
(e) amino acid residue corresponding to residue 295 in *Photinus pyralis* luciferase or to residue 297 of *Luciola mingrelica*,
25 *Luciola cruciata* or *Luciola lateralis* luciferase;
(f) amino acid residue corresponding to amino acid 14 of the *Photinus pyralis* luciferase or to residue 16 of *Luciola mingrelica*, or 17 in *Luciola cruciata* or *Luciola lateralis*;
(g) amino acid residue corresponding to amino acid 35 of the
30 *Photinus pyralis* luciferase or to residue 37 of *Luciola mingrelica*, or to residue 38 of *Luciola cruciata* or *Luciola lateralis*;
(h) amino acid residue corresponding to amino acid residue 105 of the *Photinus pyralis* luciferase or to residue 106 of *Luciola mingrelica*, 107 of *Luciola cruciata* or *Luciola lateralis* or 108
35 of *Luciola lateralis* gene;

(i) amino acid residue corresponding to amino acid residue 234 of the *Photinus pyralis* luciferase or to residue 236 of *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis*;

(j) amino acid residue corresponding to amino acid residue 420
5 of the *Photinus pyralis* luciferase or to residue 422 of *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis*;

(k) amino acid residue corresponding to amino acid residue 310 of the *Photinus pyralis* luciferase or to residue 312 of *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis*;

10 is different to the amino acid which appears in the corresponding wild type sequence and wherein the luciferase enzyme has increased thermostability as compared to an enzyme having the amino acid of the corresponding wild-type luciferase at this position.

15

Thus preferred examples of proteins of the invention are mutated wild-type luciferases where more than one amino acid, for example up to 100 amino acid residues, preferably no more than 40 amino acids, and more preferably up to 30 amino acids,
20 are different to the amino acid at the corresponding position in the appropriate wild-type enzyme.

Thus, in one preferred embodiment, the protein of the invention comprises luciferase of *Photinus pyralis*, wherein, in addition
25 to the mutation at the 357 position as described above, at least one of;

a) the amino acid residue corresponding to amino acid 354 of the *Photinus pyralis* luciferase is other than glutamate;

(b) the amino acid residue corresponding to position 215 in
30 *Photinus pyralis* luciferase or is a hydrophobic amino acid other than alanine;

(c) the amino acid residue corresponding to residue 214 in *Photinus pyralis* luciferase is other than threonine;

(d) the amino acid residue corresponding to residue 232 in
35 *Photinus pyralis* luciferase is other than isoleucine;

(e) amino acid residue corresponding to residue 295 in *Photinus pyralis* luciferase is other than phenylalanine;

(f) amino acid residue corresponding to amino acid 14 of the *Photinus pyralis* luciferase is other than phenylalanine;

(g) amino acid residue corresponding to amino acid 35 of the *Photinus pyralis* luciferase is other than leucine;

5 (h) amino acid residue corresponding to amino acid residue 105 of the *Photinus pyralis* luciferase is other than alanine;

(i) amino acid residue corresponding to amino acid residue 234 of the *Photinus pyralis* luciferase is other than aspartic acid;

(j) amino acid residue corresponding to amino acid residue 420
10 of the *Photinus pyralis* luciferase is other than serine;

(k) amino acid residue corresponding to amino acid residue 310 of the *Photinus pyralis* luciferase is other than histidine.

Alternatively, the protein of the invention comprises protein
15 the luciferase sequence of *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis* enzyme, and wherein, in addition to the mutation at position 359 as described above, at least one of

a) the amino acid residue corresponding to amino acid 356 of the *Photinus pyralis* luciferase is other than glutamate;

20 (b) the amino acid residue corresponding to position 215 in *Photinus pyralis* luciferase or is a hydrophobic amino acid other than alanine or threonine;

(c) the amino acid residue corresponding to residue 216 of *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis*
25 luciferase is other than glycine (for *Luciola mingrelica* based sequences) or asparagine (for *Luciola cruciata* or *Luciola lateralis*) based sequences;

(d) the amino acid residue corresponding to residue 234 of *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis*
30 luciferase is other than serine;

(e) amino acid residue corresponding to residue 297 of *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis* luciferase is other than leucine;

(f) amino acid residue corresponding to amino acid 16 of
35 *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis* is other than phenylalanine;

- (g) amino acid residue corresponding to residue 37 of *Luciola mingrellica*, or 38 in *Luciola cruciata* or *Luciola lateralis* is other than lysine;
- (h) amino acid residue corresponding to amino acid residue 106
5 of *Luciola mingrellica*, *Luciola cruciata* or *Luciola lateralis* is other than glycine;
- (i) amino acid residue corresponding to amino acid residue 236 of *Luciola mingrellica*, *Luciola cruciata* or *Luciola lateralis* is other than glycine;
- 10 (j) amino acid residue corresponding to residue 422 of *Luciola mingrellica*, *Luciola cruciata* or *Luciola lateralis* is other than threonine;
- (k) amino acid residue corresponding to amino acid residue 312 of *Luciola mingrellica*, *Luciola cruciata* or *Luciola lateralis* is
15 other than threonine (for *Luciola mingrellica* based sequences) or valine (for *Luciola cruciata* or *Luciola lateralis*) based sequences.

The particular substituted amino acids in any case which give
20 rise to enhanced thermostability can be determined by routine methods as illustrated hereinafter. In each case, different substitutions may result in enhanced thermostability. Substitution may be effected by site-directed mutagenesis of DNA encoding native or suitable mutant proteins as would be
25 understood by the skilled person. The invention in this case is associated with the identification of the positions which are associated with thermostability.

In general however, it may be desirable to consider
30 substituting an amino acid of different properties for the wild type amino acid. Thus hydrophilic amino acid residues may, in some cases be preferably substituted with hydrophobic amino acid residues and vice versa. Similarly, acidic amino acid residues may be substituted with basic residues.

35

For instance, the protein may comprise a protein having luciferase activity and at least 60% similarity to luciferase

from *Photinus pyralis*, *Luciola mingrellica*, *Luciola cruciata* or *Luciola lateralis* enzyme wherein in the sequence of the enzyme, at least one of;

- (a) the amino acid residue corresponding to residue 214 in *Photinus pyralis* luciferase and to residue 216 of *Luciola mingrellica*, *Luciola cruciata* or *Luciola lateralis* luciferase is mutated and is other than threonine in the case of *Photinus pyralis* luciferase; or
- (b) the amino acid residue corresponding to residue 232 in *Photinus pyralis* luciferase and to residue 234 of *Luciola mingrellica*, *Luciola cruciata* or *Luciola lateralis* luciferase is mutated and is other than isoleucine in the case of *Photinus pyralis* luciferase; or
- (c) amino acid residue corresponding to residue 295 in *Photinus pyralis* luciferase and to residue 297 of *Luciola mingrellica*, *Luciola cruciata* or *Luciola lateralis* luciferase is mutated and is for example, other than phenylalanine in the case of *Photinus pyralis* luciferase;
- and the luciferase enzyme has increased thermostability as compared to the wild-type luciferase.

The sequences of all the various luciferases show that they are highly conserved having a significant degree of similarity between them. This means that corresponding regions among the enzyme sequences are readily determinable by examination of the sequences to detect the most similar regions, although if necessary commercially available software (e.g. "Bestfit" from the University of Wisconsin Genetics Computer Group; see Devereux et al (1984) Nucleic Acid Research 12: 387-395) can be used in order to determine corresponding regions or particular amino acids between the various sequences. Alternatively or additionally, corresponding acids can be determined by reference to L. Ye et al., Biochim. Biophys Acta 1339 (1997) 39-52.

35

With respect to the possible change of the amino acid residue corresponding to residue 214 in *Photinus pyralis* luciferase,

the polar amino acid threonine is suitably replaced with a non polar amino acid such as alanine, glycine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan or cysteine. A particularly preferred substitution for the

5 threonine residue corresponding to residue 214 in *Photinus pyralis* is alanine. A more preferred substitution is cysteine. However, different polar residues such as asparagine at this position may also enhance the thermostability of the corresponding enzyme having threonine at this position.

10 Other amino acids which appear at this position in wild-type luciferase enzymes include glycine (*Luciola mingrelica*, *Hotaria paroula*), asparagine (*Pyrophorus plagiophthalmus*, GR, YG, YE and OR, *Luciola cruciata*, *Luciola lateralis*, *Lampyrus noctiluca*, *Pyrocelia nayako* *Photinus pennsylvanica* LY, KW, J19)

15 and serine (*Phrixothix*). These may advantageously be substituted with non-polar or different non-polar side chains such as alanine and cysteine.

As regards the possible change of the amino acid residue

20 corresponding to residue 232 in *Photinus pyralis* luciferase, the nonpolar amino acid isoleucine is suitably replaced with a different non polar amino acid such as alanine, glycine, valine, leucine, proline, phenylalanine, methionine, tryptophan or cysteine. Other amino acids appearing at this position in

25 wild type sequences include serine and asparagine. Suitably, these polar residues are substituted by non-polar residues such as those outlined above. A particularly preferred substitution for the residue corresponding to residue 232 in *Photinus pyralis* luciferase and to residue 234 of *Luciola mingrelica*,

30 *Luciola cruciata* or *Luciola lateralis* luciferase at group is alanine.

Changes of the amino acid residue corresponding to residue 295 in *Photinus pyralis* luciferase and to residue 297 of *Luciola*

35 *mingrelica*, *Luciola cruciata* or *Luciola lateralis* luciferase, may also affect the thermostability of the protein. (This corresponds to position 292 in *Phrixothix* luciferase.) In

general, the amino acid at this position is a non-polar amino acid phenylalanine or leucine. These are suitably changed for different non-polar amino acids. For example, in *Photinus pyralis*, the non-polar amino acid phenylalanine is suitably
5 replaced with a different non polar amino acid, such as alanine, leucine, glycine, valine, isoleucine, proline, methionine, tryptophan or cysteine. A particularly preferred substitution for the phenylalanine residue corresponding to residue 214 in *Photinus pyralis* luciferase is leucine.

10

Mutation at the amino acid residue corresponding to amino acid 14 of the *Photinus pyralis* luciferase or to amino acid 16 in *Luciola* luciferase (13 in *Phrixothrix* luciferase) is also possible. This amino acid residue (which is usually
15 phenylalanine, but may also be leucine, serine, arginine or in some instances tyrosine) is suitably changed to a different amino acid, in particular to a different nonpolar amino acid such as alanine, valine, leucine, isoleucine, proline, methionine or tryptophan, preferably alanine.

20

Mutation at the amino acid residue corresponding to amino acid 35 of the *Photinus pyralis* luciferase or to amino acid residue 37 in *Luciola mingrelica* luciferase (38 in other *Luciola* spp.) may also be effective. This amino acid varies amongst wild type
25 enzymes, which may include leucine (*Photinus pyralis*) but also lysine, histidine, glycine, alanine, glutamine and aspartic acid at this position. Suitably the amino residue at this position is substituted with a non-polar amino acid residue or a different non-polar amino acid such as alanine, valine,
30 phenylalanine, isoleucine, proline, methionine or tryptophan. A preferred amino acid at this position is alanine, where this is different to the wild-type enzyme.

Mutations at the amino acid corresponding to position 14 of the
35 *Photinus pyralis* sequence and/or mutation at the amino acid residue corresponding to amino acid 35 of the *Photinus pyralis* luciferase are preferably not the only mutation in the enzyme.

They are suitably accompanied by others of the mutations defined above, in particular those at positions corresponding to positions 214, 395 or 232 of *Photinus pyralis* luciferase.

- 5 Changes of the amino acid residue corresponding to residue 105 in *Photinus pyralis* luciferase and to residue 106 of *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis* luciferase, (102 in *Phrixothrix*) may also affect the thermostability of the protein. In general, the amino acid at this position is a non-
- 10 polar amino acid alanine or glycine, or serine in *Phrixothrix*. These are suitably changed for different non-polar amino acids. For example, in *Photinus pyralis*, the non-polar amino acid alanine is suitably replaced with a different non polar amino acid, such as phenylalanine, leucine, glycine, valine,
- 15 isoleucine, proline, methionine or tryptophan. A particularly preferred substitution for the alanine residue corresponding to residue 105 in *Photinus pyralis* luciferase is valine.

- Changes of the amino acid residue corresponding to residue 234
- 20 in *Photinus pyralis* luciferase and to residue 236 of *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis* luciferase (231 in *Phrixothrix*), may also affect the thermostability of the protein. In general, the amino acid at this position is aspartic acid or glycine and in some cases, glutamine or
- 25 threonine. These are suitably changed for non-polar or different non-polar amino acids as appropriate. For example, in *Photinus pyralis*, the amino acid residue is aspartic acid is suitably replaced with a non polar amino acid, such as alanine, leucine, glycine, valine, isoleucine, proline, methionine or
- 30 tryptophan. A particularly preferred substitution for the phenylalanine residue corresponding to residue 234 in *Photinus pyralis* luciferase is glycine. Where a non-polar amino acid residue such as glycine is present at this position (for example in *Luciola* luciferase), this may be substituted with a
- 35 different non-polar amino acid.

Changes of the amino acid residue corresponding to residue 420 in *Photinus pyralis* luciferase and to residue 422 of *Luciola mingrellica*, *Luciola cruciata* or *Luciola lateralis* luciferase (417 in *Phrixothrix* green and 418 in *Phrixothrix* red), may also
5 affect the thermostability of the protein. In general, the amino acid at this position is an uncharged polar amino acid serine or threonine or glycine. These are suitably changed for different uncharged polar amino acids. For example, in
10 *Photinus pyralis*, the serine may be replaced with asparagine, glutamine, threonine or tyrosine, and in particular threonine.

Changes of the amino acid residue corresponding to residue 310 in *Photinus pyralis* luciferase and to residue 312 of *Luciola mingrellica*, *Luciola cruciata* or *Luciola lateralis* luciferase,
15 may also affect the thermostability of the protein. The amino acid residue at this position varies amongst the known luciferase proteins, being histidine in *Photinus pyralis*, *Pyrocelia nayako*, *Lampyrus noctiluca* and some forms of *Photinus pennsylvanica* luciferase, threonine in *Luciola mingrellica*,
20 *Hotaria paroula* and *Phrixothrix* (where it is amino acid 307) luciferase, valine in *Luciola cruciata* and *Luciola lateralis*, and asparagine in some *Pyrophorus plagiophthalmus* luciferase. Thus, in general, the amino acid at this position is
25 hydrophilic amino acid which may be changed for a different amino acid residue which increases thermostability of the enzyme. A particularly preferred substitution for the histidine residue corresponding to residue 310 in *Photinus pyralis* luciferase is arginine.

30 Other mutations may also be present in the enzyme. For example, in a preferred embodiment, the protein also has the amino acid at position corresponding to amino acid 354 of the *Photinus pyralis* luciferase (356 in *Luciola* luciferase) changed from glutamate, in particular to an amino acid other than
35 glycine, proline or aspartic acid. Suitably, the amino acid at this position is tryptophan, valine, leucine, isoleucine are asparagine, but most preferably is lysine or arginine. This

mutation is described in WO 95/25798. It has been found that hydrophobic residues at this position enhance the wavelength shift of the enzyme. Furthermore, the presence of a large hydrophobic (V or I), polar (N) or positively charged (K or R) amino acid at position 354 enhances thermostability.

In an alternative preferred embodiment, the protein also has the amino acid at the position corresponding to amino acid 217 in *Luciola luciferase* (215 in *Photinus pyralis*) changed to a hydrophobic amino acid in particular to isoleucine, leucine or valine as described in EP-A-052448.

Proteins of the invention include both wild-type and recombinant luciferase enzymes. They have at least 60% similarity to wild sequences such as those of *Photinus pyralis*, *Luciola mingrelia*, *Luciola cruciata* or *Luciola lateralis* enzyme in the sense that at least 60% of the amino acids present in the wild-type enzymes are present in the proteins of the invention. Such proteins can have a greater degree of similarity, in particular at least 70%, more preferably at least 80% and most preferably at least 90% to the wild-type enzymes listed above. Similar proteins are of this type include allelic variants, proteins from other insect species as well as recombinantly produced enzymes. They can be readily identified in that they are encoded by nucleic acids which hybridise with sequences which encode wild-type enzymes under stringent hybridisation conditions. Such conditions would be well understood by the person skilled in the art, and are exemplified for example in Sambrook et al. (1989) Molecular Cloning, Cold Spring Harbor Laboratory Press). In general terms, low stringency conditions can be defined as 3 x SSC at about ambient temperature to about 65°C, and high stringency conditions as 0.1 x SSC at about 65°C. SSC is the name of a buffer of 0.15M NaCl, 0.015M trisodium citrate. 3 x SSC is three times as strong as SSC and so on.

In particular, the similarity of a particular sequence to the sequences of the invention may be assessed using the multiple

alignment method described by Lipman and Pearson, (Lipman, D.J. & Pearson, W.R. (1985) Rapid and Sensitive Protein Similarity Searches, Science, vol 227, pp1435-1441). The "optimised" percentage score should be calculated with the following
5 parameters for the Lipman-Pearson algorithm: ktup =1, gap penalty =4 and gap penalty length =12. The sequences for which similarity is to be assessed should be used as the "test sequence" which means that the base sequence for the comparison, such as the sequence of *Photinus pyralis* or any of
10 the other sequences as recorded in Ye et al., supra., should be entered first into the algorithm.

Particular examples of proteins of the invention are wild-type luciferase sequence with one or more of the mutations as
15 outlined above.

The invention further provides nucleic acids which encode the luciferases as described above. Suitably, the nucleic acids are based upon wild-type sequences which are well known in the
20 art. Suitable mutation to effect the desired mutation in the amino acid sequence would be readily apparent, based upon a knowledge of the genetic code.

In a preferred embodiment of the invention, the nucleic acid is
25 a synthetic gene. Suitably, the synthetic gene is engineered to remove codons rarely found in highly expressed genes from common expression hosts such as *E. coli* and, at the same time, avoid the introduction of codons rarely found in genes coding for beetle luciferases. This approach ensures that the new gene
30 has a codon utilisation that is optimal for both *E. coli* and insect expression systems.

For example, wherever possible the codons for the amino acids arg, leu, ile, gly and pro were changed to CGT or CGC (arg),
35 CTG, CTT or CTC (leu), ATC or ATT (ile), GGT or GGC (gly), and CCG CCA or CCT (pro), thus eliminating rare codons. In the case of the synthetic gene illustrated below (SEQ ID NO 1) and in Figure 14, this resulted in a total of 139 silent mutations

creating 62 new non-rare codons (11% of the total). The first 8 nucleotides shown in Figure 14 form part of the ribosome binding site and thus do not code. The coding sequence begins with the methionine residue indicated by an up arrow. This
5 coding sequence and closely similar sequences, for example sequences which have at least 90% similarity or preferably at least 95% similarity form a preferred aspect of the invention.

Another useful feature which may be employed when producing a
10 synthetic assembly is the incorporation of new unique restriction sites. These sites make mutagenesis, in particular combinatorial cassette mutagenesis, of the gene simpler and more efficient. In particular, it may be desirable to create unique restriction sites within the cDNA coding for subdomain B
15 in the enzyme. Additionally creation of a unique restriction site at the extreme 3' end of the gene to allow simple fusions and/or removal of the peroxisome targeting sequence may be advantageous.

20 In the example illustrated hereinafter, nine new unique restriction sites were engineered, mostly in the central third of the gene, and a unique Hind III site was generated at the extreme 3' end of the gene to allow for simple C-terminal fusions (Figure 12).

25 Finally, use of a synthetic gene allows for the introduction of mutations to increase the thermostability of the gene product, or to otherwise modify the properties of the product as desired. In the Example illustrated hereinafter for instance,
30 three non-silent mutations were engineered to introduce the thermostabilising amino acid changes T214C, E354K and D357F into the polypeptide.

The nucleic acids of the invention are suitably incorporated
35 into an expression vector such as a plasmid under the control of control elements such as promoters, enhancers, terminators etc. These vectors can then be used to transform a host cell, for example a prokaryotic or eukaryotic cell such as a plant or

animal cell, but in particular a prokaryotic cell such as *E. coli* so that the cell expresses the desired luciferase enzyme. Culture of the thus transformed cells using conditions which are well known in the art will result in the production of the
5 luciferase enzyme which can then be separated from the culture medium. Where the cells are plant or animal cells, plants or animals may be propagated from said cells. The protein may then be extracted from the plants, or in the case of transgenic animals, the proteins may be recovered from milk. Vectors,
10 transformed cells, transgenic plants and animals and methods of producing enzyme by culturing these cells all form further aspects of the invention.

The *Photinus pyralis* D357Y mutant luciferase was created by
15 random mutagenesis as described hereinafter. It was found that the D357Y single point mutation produces a large colour shift in the wavelength of light emitted and also has greater thermostability than wild type luciferase. Further investigations have revealed that a range of substitutions at
20 this position give rise to good thermostability and/or to large colour shifts.

Particular examples of mutant enzymes of *Photinus pyralis* which fall within the scope of the invention include the following:

25

D357Y

D357F

D357W

D357K

30 D357N

D357I

E354I/D357Y

E354V/D357Y

E354C/D357Y

35 E354R/D357Y

E354S/D357Y

E354N/D357Y

E354K/D357M

E354R/D357L
E354W/D357W
E354H/D357W
E354R/D357F
5 E354K/D357F
E354S/D357F
E354M/D357F
E354A/D357R
E354A/D357F
10 E354T/D357Y
E354A/D357N
I351M/E354R/D357V
E354S/D357V
E354R/D357W
15 E354R/D357M
E354R/D357S
E354N/D357S

or equivalents of any of these when derived from the
20 luciferases of other species.

The mutations for the creation of the above mutants were introduced to the luciferase gene on plasmid pET23 by site-directed mutagenesis, (PCR) or combinatorial cassette
25 mutagenesis. The oligonucleotides added to the PCR reaction in order to effect the relevant mutations are given below.

It has been reported previously that the effect of point mutations at the 354 and 215 positions are additive. This
30 invention provides the possibility of combining three or more such mutations to provide high thermostability in a mutant enzyme which has a large colour shift.

Luciferase proteins of the invention will advantageously be
35 employed in any bioluminescent assay which utilises the luciferase/luciferin reaction as a signalling means. There are many such assays known in the literature. The proteins may therefore be included in kits prepared with a view to

performing such assays, optionally with luciferin and any other reagents required to perform the particular assay.

The invention will now be particularly described by way of
5 example with reference to the accompanying diagrammatic drawings in which:

Figure 1 is a log graph showing % remaining activity versus
time of 45°C incubation of several mutant enzymes in accordance
10 with the invention;

Figure 2 shows the spectral peaks obtained by incubating *E. coli* cells expressing luciferase enzymes in a citrate buffer with D-luciferin where the enzyme used is (a) recombinant
15 wild-type *Photinus pyralis* luciferase, (b) a D357K mutant, (c) a D357N mutant, (d) a D357W mutant, (e) a D357I mutant, (f) a D357F mutant, (g) a D357Y mutant and (h) a double mutant E354I + D357Y;

20 Figure 3 is a graph showing the % remaining activity versus time of three mutant enzymes, E354I, D357Y and the double mutant (DM) E354I/D357Y;

Figure 4 shows the emission spectra of (a) recombinant wild
25 type enzyme and (b) the double mutant (DM) E354I/D357Y;

Figure 5 is a graph showing the rate decay of photon emissions of recombinant wild-type (♦) r-wt and a D357K mutant enzyme (!).
30

Figure 6 shows molecular modelling diagram, illustrating a potential CoA binding pocket within the luciferase enzyme;

Figure 7 shows the in vivo bioluminescent spectra emitted by *E. coli* cells expressing mutant *P. pyralis* luciferase D357Y (a)
35 growth on LB; (b) growth on minimal medium and sodium acetate; (c) growth on minimal medium and glucose;

Figure 8 shows the in vivo bioluminescent spectra emitted by *E. coli* cells expressing mutant *P. pyralis* luciferase E354K/D357M (a) growth on LB; (b) growth on minimal medium and sodium acetate; (c) growth on minimal medium and glucose;

Figure 9 is a graph showing the effect of CoA on spectral distribution of light emitted by mutant *P. pyralis* luciferase D357Y;

10

Figure 10 is a graph showing the normalised data of the effect of CoA on spectral distribution of light emitted by mutant *P. pyralis* luciferase D357Y;

Figure 11 is a graph showing the effect of CoA on spectral distribution of light emitted by mutant *P. pyralis* luciferase E354I/D357Y (Figure 11a) and normalised data (Figure 11b);

Figure 12 illustrates the restriction sites modifications utilised in the construction of a synthetic luciferase gene;

Figure 13 illustrates constructs used in the synthesis of a luciferase gene;

Figure 14 shows the cDNA sequence (SEQ ID NO 1) of the synthetic luciferase gene (including nucleotides 1-8 which form part of the ribosome binding site but are not coding) and the encoded amino acid sequence which starts at the methionine residue indicated by the up arrow (SEQ ID NO 2); and

30

Figure 15 illustrates the thermostability of mutants including the mutant encoded by the synthetic gene at 50°C.

Example 1Identification and Characterisation of Mutant Luciferase

Two libraries of firefly (*Photinus pyralis*) luciferase, created used error-prone PCR [M. Fromant et al., Anal. Biochem. (1995) 224, 347-353], were prepared. One library comprised of error-prone PCR products of the full length *luc* gene, cloned into the T7 expression system pET23a, (Novagen Inc., Madison, WI, U.S.A.). A second library consisted of the error-prone PCR products of a short section of the *luc* gene, covering amino acids 199-352, cloned in the vector pBSK(+), (Stratagene, La Jolla, CA, U.S.A.).

The pET23a library was expressed in *E. coli* strain BL21(DE3), (*E. coli* B F dcm ompT hsdS($r_B^-m_B^-$) gal λ (DE3)).

The pBSK(+) library was expressed in HB101 *E. coli* cells, (*supE44 ara14 galK2 lacY1 Δ (gpt-proA)62 rpsL20 (Str^r) xyl-5 mtl-1 recA13 Δ (mrcC-mrr) HsdS⁻ (r^-m^-)*). pET23a and pBSK(+) both carry the gene for β -lactamase and confer ampicillin resistance to *E. coli* cells harbouring the plasmid.

An *E. coli* strain was transformed with the prepared library by electroporation, using a BIORAD *E. coli* Pulser, and grown overnight at 37°C on LB agar, containing ampicillin at a concentration of 50 μ g/ml. The cells were transferred to nylon membranes, (Osmonics, Minnetonka, Minnesota, U.S.A.), and sprayed with luciferin solution (500 μ M D-luciferin, potassium salt, in 100mM sodium citrate buffer, pH 5.0). The colonies were viewed using an AlphaImager™ 1200 Documentation and Analysis System (Flowgen, Lichfield, Staffordshire, UK). This integrated the bioluminescence emitted over a specified period of time to produce an image of the light emitted by the colonies. The brightness of luminescence was taken as an indication of the thermostability of luciferase.

The colonies were then screened for thermostability. Colonies were selected on the basis of brightness of light emitted and were isolated for further characterisation. In some screens, the *E. coli* colonies were incubated at 42°C for 2 hours prior to screening so that the thermostable mutants could be selected. Colonies isolated from the primary screen were patched onto nylon membranes and also grown overnight in LB medium containing ampicillin. The patches were sprayed with luciferin solution and viewed in the AlphaImager™. This secondary screen helped to positively identify clones for *in vitro* analysis of luciferase activity. *E. coli* clones expressing possible thermostable enzymes were assayed *in vitro* for luciferase activity and thermostability.

In vitro assays for luciferase activity were performed at room temperature using the Promega Luciferase Assay System (Promega Corporation, Madison, WI, U.S.A.).

The luciferase reaction was initiated by the addition of 10µl crude cell extract to 100µl Promega Luciferase Assay Cocktail (1 in 2 dilution). The resultant bioluminescence was measured using a Biotrace M3 luminometer.

Crude cell extracts were prepared as described in the Promega technical bulletin no. 101. Aliquots of *E. coli* overnight cultures were lysed in cell culture lysis reagent, (25mM Tris-phosphate pH7.8, 2mM dithiothreitol (DTT), 2mM 1,2-diaminocyclohexane-N,N',N'-tetraacetic acid, 10% glycerol, 1% Triton X-100, 1.25 mg/ml hen lysozyme) for 10 minutes at room temperature. Crude lysate were then stored on ice prior to assay.

The properties of the enzymes were further tested in time-dependent inactivation studies. Eppendorf tubes containing 50µl aliquots of crude cell extract were incubated in a water bath at a given temperature. At set time points tubes were

removed and cooled on ice prior to assay. Remaining luciferase activity was expressed as a percentage of the original activity.

- 5 Log graphs of percentage remaining activity versus time of incubation were plotted and used to calculate $t_{1/2}$ values. $T_{1/2}$ is the time taken for the enzyme to lose 50% of its original activity after incubation at a given temperature. $T_{1/2}$ values, (time for activity to reduce to 50% of original activity), were
10 determined in crude extracts at 37°C from log graphs of % remaining activity versus time (not shown).

- Plasmid DNA from *E. coli* clones expressing the most thermostable luciferase as determined above, was sequenced in
15 order to determine the mutations responsible for the thermostability of the enzyme.

- Plasmid DNA was prepared using the QIAGEN QIAprep Spin Miniprep Kit, (QIAGEN Ltd, Crawley, W. Sussex, UK), following the
20 protocol for using a microcentrifuge (QIAprep Miniprep Handbook 04/98).

- All DNA sequencing was undertaken by Babraham Tech^{nix}, Cambridge, UK, using an ABI PRISM™ 377 DNA Sequencer and the
25 ABI PRISM™ BigDye™ Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer Applied Biosystems) which is based upon the dideoxy chain termination method [F. Sanger et al., Proc. Natl. Acad. Sci. U.S.A. 74, (1977) 5463-5467].

- 30 As a result of this work, the novel mutant D357Y was identified.

- The crystal structure of luciferase [E. Conti et al., Structure, 4 (1996) 287-298] shows that position 357 is
35 situated on the surface of the protein and is close to position 354, which can affect both thermostability and spectral

properties. This indicates that this region could be important in terms of the thermostability of the enzyme.

D357Y is a particularly thermostable mutant, being the most
5 thermostable luciferase, with a single amino acid change.

Example 2

Site-Directed Mutagenesis to create other 357 mutants

In order to evaluate different mutations at the 357 position,
10 site-directed mutagenesis was performed using the Stratagene
QuikChange™ Site-Directed Mutagenesis Kit, (Stratagene, La
Jolla, CA, U.S.A.). The plasmid pPW601a J54, (PJW, MoD Report,
3/96), was used in all site-directed mutagenesis. All products
of the mutagenesis reactions were transformed into *E. coli*
15 strain XL1-Blue, [*e14*⁻(*mcrA*⁻) Δ (*mcrCB-hsdSMR-mrr*)171 *endA1*
supE44 thi-1 gyrA96 relA1 lac recB recJ sbcC umuC::Tn5 (Kan^r)
uvrC [F' proAB lacI^qZAM15 Tn 10 (Tet^r) Amy Cam^r]]
Oligonucleotide primers were synthesized by Sigma-Genosys Ltd.,
Cambridge, UK and were designed using an intelligent doping
20 system [A.R Arkin et al., Bio-technology, (1992)10, 297-300,
W,. Huang et al., Anal. Biochem. 218, 454-457] were used to
design degenerate oligonucleotide primers to produce groups of
possible mutations rather than using individual primers for
each amino acid substitution.

25

In this way, libraries of amino acid substituted luciferase
mutants were produced.

The following oligonucleotides (and their complementary
partners) were used:

Oligonucleotide Primer (5'→3')	Amino Acid Substitution
cacccgaggggggat[tat]aaaccggg'gcgcgg (SEQ ID NO 4)	Y
cacccgaggggggat[(gac)(tc)(c)]aaaccggg'gcgcggtcgg (SEQ ID NO 5)	A,I,L,T,V,P
cacccgaggggggat[(t)(gat)(gc)]aaaccggg'gcgcggtcgg (SEQ ID NO 6)	C,F,L,W,Y,X
cacccgaggggggat[(ac)(ga)(gc)]aaaccggg'gcgcggtcgg (SEQ ID NO 7)	R,S,K,N,H,Q

The libraries of mutants were screened as previously for thermostability. The number of colonies to be screened was
 5 calculated using the equation [S. Climie et al., J. Biol. Chem. 265 (1990) 18776-18779]

$$N = [\ln(1-P)] / [\ln((n-1)/n)]$$

Where N is the number of colonies to be screened, n is the
 10 number of possible codons at the target position and P is the probability that every codon in the mixture is sampled for screening at least once. The calculation was based on P=0.95. The mutants obtained from site-directed mutagenesis were
 15 assayed for luciferase activity and characterised in time-dependent thermoinactivation studies.

Mutants identified as desirable in this way were grown in 400ml LB medium, containing ampicillin, to $A_{260} \approx 0.5$. Luciferase
 expression was then induced by addition of isopropyl β -
 20 thiogalactoside (IPTG) to a final concentration of 1mM. The cells were then incubated at 30°C, with shaking, for 3 hours prior to harvesting by centrifugation. The resultant cell pellet was resuspended in 10ml B-PER™ Protein Extraction
 Reagent, (Pierce Chemical Company, Rochford, U.S.A.), 1mM DTT
 25 to produce a crude extract, following the B-PER™ protocol for Maxi-Scale Bacterial Protein Extraction. Reconstituted Sigma Protease Inhibitor Cocktail, 500 μ l, (Product No. P8465, Sigma,

Saint Louis, Missouri, U.S.A.), was added to the B-PER™ solution to inhibit endogenous proteases. The cell lysate was then centrifuged at 30 000g for 30 minutes.

- 5 The supernatant of the crude extract was subjected to fractionation with ammonium sulphate. The fraction that precipitated between 30% and 55% saturation contained luciferase activity. This material was resuspended in 0.5ml Tris HCl pH8.0, 1mM DTT and used for thermoinactivation and
10 spectral studies.

The replacements D357L, T, V, W, R, I, S, K, N and F were introduced. These mutants were characterised in *in vitro* thermoinactivation studies of crude extracts.

- 15 The partially purified extracts were diluted, 1 in 11, into a thermoinactivation buffer: 50mM potassium phosphate buffer pH7.8 containing 10% saturated ammonium sulphate, 1mM dithiothreitol and 0.2% BSA.

- 20 110µl aliquots of protein solution were incubated at 40°C or 45°C for set periods of time and cooled on ice prior to assay. Luciferase activity was then measured as described in Example 1, using Promega Luciferase Assay Reagent (1 in 2 dilution).

- 25 The results are shown in Tables 2 & 3 and in Figure 1. T_{1/2} values were determined in crude extracts at 40°C (Table 2) and 45°C (Table 3).

Table 2

Mutant	T _{1/2}
D357K	2.2
D357R	4.2
D357S	4.6
D357N	4.8
D357V	5.9
D357T	7.3
D357L	11.3
D357I	18.0
rWT	<1.0

Table 3

Mutant	T _{1/2}
D357W	2.5
D357F	6.5
D357Y	10.4
RWT	<1.0

All the substitutions displayed enhanced thermostability in comparison to recombinant wild type.

5

Example 3

Changes in Wavelength of Emitted Light

Amino acid replacements at position 357 were also observed to affect the *in vivo* spectra of light emitted by the enzyme. An aliquot, (250µl), of *E. coli* cell cultures, as described in Example 2 were grown overnight at 37°C, was spun down in a microcentrifuge and the supernatant removed. Cells expressing different mutant luciferases were incubated in a citrate buffer (pH5.0) containing 150µl D-luciferin and the light emitted from the *in vivo* reaction was analysed by measuring the emission spectra using a SPECTRAMax[®] Microplate Spectrofluorometer, (Molecular Devices Corp. California, U.S.A.). Large changes in the spectral peak as well as the distribution of wavelengths was observed for the mutants D357Y, F and I (Figure 2(a)-(g)). These results are summarised in Table 4 below.

In addition, the *in vivo* luminescence of the mutants was assessed by eye in a dark room. The D357 mutants displayed a variety of colours in their luminescence spectra. In particular, D357Y, F and I showed significant shifts to longer wavelengths of emitted light.

25

In some cases, (e.g. D357F), the change in colour of light emission appeared to be due, not only to a shift in λ_{\max} , but to a difference in contributions to the spectra from different wavelengths of visible light.

5

Table 4

Mutant	λ_{\max} (nm)	Deviation from rWT (nm)
rWT	558	-
D357K	556	-2
D357N	558	0
D357W	558	0
D357I	606	+48
D357F	611	+53
D357Y	613	+55

Recombinant wild type (r-wt) enzyme was used for comparison of λ_{\max} of *in vivo* light emission of some of the 357 mutants.

10 D357Y, F and I display considerable shifts in their wavelength maxima.

Example 4

Enzyme properties in the presence or absence of CoA

15 D357Y was partially purified by ammonium sulphate precipitation, as described in the Example 1. This partially purified D357Y enzyme (5 μ l) was mixed with 150 μ l Promega Luciferase Assay Reagent. Another aliquot was mixed with an equivalent assay buffer in which CoA is absent, (25mM Tris

20 Tricine pH7.8, 5.0mM MgSO₄, 0.1mM EDTA, 2mM DTT, 470 μ M D-luciferin, 530 μ M ATP). The emission spectra of the two reactions were measured and are shown in Figures 9 and 10.

The spectra display a marked difference in bioluminescent emission in the absence and presence of CoA, with dramatic

25 shift in λ_{\max} . The effect of CoA on the kinetics of the luciferase reaction can also be seen by in the difference in RLU scales. (RLU - Relative Light Units).

This difference in emission gives rise to the possibility of using the enzyme in an assay to detect the presence of CoA.

Example 5

5 Preparation and Properties of Double Mutant

Using site-directed mutagenesis as described in Example 2, a double mutant of E354I + D357Y was engineered in order to study any cumulative effects upon thermostability and colour of light emission.

10

The partially purified double mutant, E354I + D357Y, was diluted, 1 in 11, into a thermoinactivation buffer: 50mM potassium phosphate buffer pH7.8 containing 10% saturated ammonium sulphate, 1mM dithiothreitol and 0.2% BSA.

15

110µl aliquots of protein solution were incubated at 45°C for set periods of time and cooled on ice prior to assay. Luciferase activity was then measured as previously, using Promega Luciferase Assay Reagent (1 in 2 dilution).

20

The double mutant displayed a marked increase in thermostability in comparison to the single mutants E354I and D357Y individually, (see Figure 3). Thermoinactivation studies of partially purified double mutant confirmed the increased
25 thermostability of the mutant, giving a $t_{1/2}$ value of 7.7 min when inactivated at 45°C.

It was noted that the double mutant displays a much deeper red colour of luminescence than the individual mutants of E354I and
30 D357Y, displaying additivity of colour of luminescence.

The emission spectra of recombinant wild type and the crude extract of the double mutant E354I + D357Y were also measured using the assay buffer described in Example 3.

35

Emission spectra measured *in vivo* give a λ_{max} of 611nm. However, the spectrum has a greater contribution of

luminescence from the red region of wavelengths, leading to its deeper red appearance when visualised by eye. Emission spectra in crude extracts displayed a definite change in spectral shape and a wavelength shift of 44nm, relative to rWT, (see Figure 4).

The *in vivo* emission spectrum of the double mutant shows both a sharpening of the bandwidth for the peak wavelength of emitted light (613nm) and a decrease in the contribution from wavelengths of light in the region 540-560nm.

The dramatic effect of these mutations indicates the importance of this region of the enzyme to the colour of bioluminescent light.

15

Example 6

Improved Photon Flux

The *in vivo* bioluminescence of *E. coli* cells expressing the mutant D357K was observed to be very bright relative to the other mutants at this position. The flash kinetics of this enzyme was analysed using a luminometer, which could measure the rate of photon emission over time. Aliquots of *E. coli* cell free extracts containing recombinant wild type enzyme or the mutant D357 were added to a luciferase assay cocktail, which did not contain any reagents that would promote glow kinetics e.g. coenzymeA. The rate of decay of photon emission was measured over time (15s) for both enzymes was observed to be significantly slower for the mutant D357K (Figure 4). In other words the mutant enzyme has reaction kinetics, which are inhibited to a lesser degree, over at least the first 15 seconds of the reaction, than the recombinant wild type enzyme.

Example 7

Combinatorial cassette mutagenesis at positions E354 and D357

Step 1

Engineering plasmid pPW601aJ54 for cassette mutagenesis

Two new unique restriction sites were introduced into the *luc* gene, in the plasmid pPW601a/J54, using two pairs of synthetic

oligonucleotides (see below). A total of six silent mutations introduced a SpeI and a KpnI restriction site, 63 base pairs apart, within the gene. Plasmid containing these new sites was called pPW601aJ54SpeI/KpnI. The presence and proximity of these
 5 restriction sites makes it possible to use combinatorial cassette mutagenesis to explore the effects of random substitutions at amino acid positions 354 and 357 in the primary sequence of firefly luciferase.

10 SpeI (a) 5'-gggctcactgagact**acTAGT**gctattatgattacacccg-3'
nt1021- nt1060 (SEQ ID NO 8)

SpeI (b) 5'-cggggtgtaatcagaatagc**ACTAg**tagtctcagtgagccc-3'
 (SEQ ID NO 9)

15

KpnI (a) 5'-ggcgcgggtcggtaaagt**GgtAcc**attttttgaagcg-3' nt1078-
nt1113 (SEQ ID NO 10)

KpnI (b) 5'-cgcttcaaaaaat**ggT**acCactttaccgaccgcgcc-3'
 20 (SEQ ID NO 11)

Nucleotides highlighted in bold form the endonuclease recognition site and those in upper case the position of the point mutations necessary to create the site.

25 Step 2

Cassette design and library construction

A pair of synthetic oligonucleotides was synthesised which when annealed created a double stranded cassette which could be ligated directly into plasmid pPW601aJ54SpeI/KpnI digested at
 30 the new restriction sites. The cassette was designed to introduce all possible combinations of the 20 naturally occurring amino acids at positions 354 and 357 in the primary sequence.

35 Looplib2A 5'-
 ctagtgtctattctgattacacccNNG/CggggatNNG/Caaaccgggcgcggtcggtaaagtg
 gta-3' (SEQ ID NO 12)

Looplib2B 5' -
cactttaccgaccgcgcccgggtttG/CNNatccccG/CNNgggtgtaatcagaatagca-3'
(SEQ ID NO 13)

2µg of each of the loop library oligonucleotides was mixed in a
5 buffer containing 50mM Tris-HCl pH 7.4, 25mM NaCl, and heated
to 100°C for 3min. This solution was then cooled slowly in a
heating block to <50°C to anneal the complimentary sequences.
The annealed oligonucleotides were then ligated into plasmid
pPW601aJ54SpeI/KpnI, which had been digested with SpeI and
10 KpnI. Aliquots of the ligation reaction were then used to
transform *E. coli* HB101 cells using electroporation. After
electroporation transformed cells were plated out on LB agar
plates containing 50µg/ml ampicillin and grown overnight at
37°C. The following day 869 colonies were picked at random from
15 the plates and used to inoculate 1ml of LB containing
ampicillin in 96 square-well plates (Beckman). The plates were
covered and the cells grown overnight at 37°C with shaking.

Step 3

20 *In vivo* screening the randomly selected clones

The next morning 50µl aliquots of the stationary phase
overnight cultures were transferred to two clear plastic round
bottom 96 well microtitre plates (Dynex). One plate was covered
and incubated on a heated block for 8 minutes (block surface
25 temperature 45°C) whilst the other was kept at 37°C. The *in vivo*
luciferase activity in the cells from both plates was then
detected and recorded, at room temperature, by adding 50µl of a
100mM sodium citrate buffer pH 5.0 containing 0.5mM D-luciferin
to the wells and then transferring the plate to a video camera
30 imager capture system (Alpha Imager). The light emitted by the
heated and control cultures was integrated over 1 or 2 minutes
and the image recorded on thermal paper film.

Seventy-nine cultures exhibiting the greatest bioluminescence,
35 as determined by the brightness of the image recorded on film,
were selected for a second round of screening. This time the

cultures were incubated for 16 minutes on the heating block prior to being assayed. Of the 55 clones selected from the *in vivo* thermostability screens 25 were chosen for *in vivo* spectral analysis. These clones were grown overnight in LB at 37°C and the next morning 200µl of the overnight cultures was centrifuged and the *E. coli* cell pellets were resuspended in 150µl of 100mM sodium citrate buffer pH 5.0 containing 0.5mM D-luciferin. The resuspended cells were then placed in a white plastic microtitre plate and the *in vivo* bioluminescent emission spectrum emitted by each of the mutant luciferases was analysed using a Molecular Devices Spectramax 96 well plate fluorimeter. The results are summarised in the Table 1 below.

Step 4

15 Identification of mutations

Plasmid DNA was prepared from the 25 clones selected by *in vivo* screening and sequenced using gene specific sequencing primers. Mutations resulting in amino acid changes at positions 354 and 357 in the primary sequence were identified. One mutant, also contained an additional mutation resulting in an amino acid substitution at position I351 (Table 5).

Table 5

<u>Mutant</u>	<u>Mutations</u>	<u>Peak Wavelengths (nm)</u>
<u>Enzyme</u>		
1	E354V/D357Y	614
2	E354I/D357Y	612
3	E354C/D357Y	612
4	E354R/D357Y	600
5	E354S/D357Y	612
6	E354N/D357Y	608
7	E354K/D357M	556, 606
8	E354R/D357L	588
9	E354W/D357W	610
10	E354H/D357W	606
11	E354R/D357F	596
12	E354K/D357F	608

<u>Mutant</u> <u>Enzyme</u>	<u>Mutations</u>	<u>Peak Wavelengths (nm)</u>
13	E354S/D357F	610
14	E354M/D357F	610
15	E354A/D357R	556
16	E354A/D357F	610
17	E354T/D357Y	612
18	E354A/D357N	560
19	I351M/E354R/D357V	606
20	E354S/D357V	556, 608
21	E354R/D357W	600
22	E354R/D357M	596
23	E354R/D357S	592
24	E354N/D357S	600
rWT	E354/D357	552

where rWT signifies recombinant wild-type.

A number of mutant luciferases were selected from the *in vivo* assays for thermostability. The majority of these luciferases also show large changes in the *in vivo* spectrum of emitted light with many showing greater contributions from longer wavelengths of light (>580nm). A number of spectra also showed a significant narrowing of bandwidth around a single peak of 610-614nm.

Replacements of E354 and D357 with a hydrophobic and an aromatic amino acid respectively e.g. E354V, D357Y results in the largest change in the *in vivo* spectrum which shows a single peak, of narrow bandwidth, around 612nm.

Example 8

In vitro screening for thermostability

Cell free extracts of the selected clones were prepared by lysis and the thermostability of the luciferase from each extract was determined in a thermal inactivation experiment. 50µl of each extract was placed in an eppendorf tube and

incubated in a waterbath heated to 45°C for 4, 9 and 16 minutes. At the appropriate timepoint the aliquot was removed and the remaining luciferase activity measured. Table 6 shows the percent remaining activity versus time for all mutant enzymes as well as recombinant wild type.

Table 6

Enzyme No. (see Table 5)	Percentage activity remaining after incubation at 45°C			
	0 min	4 min	9 min	16 min
1	100	95	87	75.4
2	100	99	84.7	67.7
3	100	92	73	53.3
4	100	94	89	71.4
5	100	85	72.2	53
6	100	93	84.8	71
7	100	63.7	31	11.7
8	100	58.6	19	4.9
9	100	85.4	65.3	42.3
10	100	65.5	27.8	10.6
11	100	88.6	70	54
12	100	90	69	52
13	100	83	60.5	39
14	100	80	61	39
15	100	1.7	0.1	nd
16	100	90	76	63
17	100	91	78	60
18	100	19	1.8	nd
19	100	17	1.4	nd
20	100	17	1.1	nd
21	100	71	63	34
22	100	80	40	21
23	100	29	4	0.6
24	100	28	4	0.4
25 (D357K)	100	0.1	nd	nd
rWT	100	0.05	nd	nd

where "nd" indicates not done.

The results indicate that the most thermostable luciferases were those with an aromatic amino acid at position 357 (Y, F or W) and a large hydrophobic (V or I), polar (N) or positively charged (K or R) amino acid at position 354.

5

Example 9

Effect of growth conditions on the in vivo spectrum of emitted light.

10 The effect of different carbon sources on the spectrum of emitted light from *E. coli* BL21(DE3) cells expressing mutant luciferases D357Y or E354K + D357M (7 above) was investigated.

15 A 50ml culture of cells was grown to mid log phase on LB medium and then harvested by centrifugation. The cell pellet was resuspended in 1ml of sterile distilled water and a 100ul aliquot of this suspension was then used to inoculate 5ml of fresh LB, M9 minimal medium + 2mM sodium acetate or M9 minimal medium + 2mM glucose in a 25ml Sterilin tube. The cultures were allowed to continue growing, at 37°C with shaking, and after 90 minutes (D357Y) or 120 minutes (enzyme 7) a 200µl aliquot of cells was removed centrifuged and resuspended in 150ul of 100mM sodium citrate buffer pH 5.0 containing 0.5mM D-luciferin. The resuspended cells were then placed in a microtitre plate and the *in vivo* bioluminescent emission spectrum emitted by each of the mutant luciferases was analysed using a Molecular Devices Spectramax 96 well plate fluorimeter. The results are shown in Figures 7 and 8.

30 The results show that switching from a rich medium (LB) (Figure 7a, 8a) to a defined minimal medium with either acetate (Figure 7b, 8b) or glucose (Figure 7c, 8c) as the sole carbon source resulted in shifts to longer wavelengths of emitted light and a reduction in the contribution from shorter wavelengths.

Example 10Purification and spectral characterisation of recombinant wild type, and mutant luciferases

Recombinant wild type *Photinus pyralis* enzyme and the mutant
5 luciferases D357Y and E354I + D357Y were purified to
homogeneity in order to analyse the effect of the cofactor
coenzyme A on the spectrum of the bioluminescent reaction. All
three luciferases were purified as fusions to a 143 amino acid
carbohydrate binding module (CBM) from the anaerobic fungus
10 *Piromyces equii*. This CBM has been shown to bind selectively to
acid swollen cellulose and the soluble carbohydrates
galactomannan and glucomannan, forming the basis for a simple
single step affinity purification scheme.

15 Luciferases fused to the CBM can be bound to cellulose in crude
cell free extracts, washed, and then eluted selectively using
soluble polysaccharides. Fusion proteins purified this way were
used in assays to measure the wavelengths of emitted light in
reactions containing different amounts of coenzyme A. Enzyme
20 (5µl) was added to 100µl of assay reagent, 25mM Tris-Tricine pH
7.8, 5.0mM MgSO₄, 0.1mM EDTA, 530µM ATP and 470µM D-luciferin,
containing different amounts of coenzyme A. Figures 9-11 show
the effect of increasing concentrations of coenzyme A on the
spectrum of light emitted by the purified luciferases D357 and
25 E354I + D357Y.

In vivo assays of the spectrum of bioluminescent light emitted
by *E. coli* cells expressing firefly luciferase fused to the C-
terminus of the fungal CBM did not show any significant
30 differences from cells expressing the native luciferase
Similarly, *in vitro* assays of the spectrum of bioluminescent
light emitted by a commercial source of purified recombinant
luciferase (Promega) were identical to the spectrum emitted by
the fusion protein.

35

The observed differences are therefore associated with the
concentrations of CoA. As the concentration of coenzyme A

increases the spectral distribution alters and at the highest concentrations of CoA the spectrum is dominated by wavelengths in the region 590-630nm with a pronounced peak at 610nm. The spectral shift is most marked for the double mutant where there is a significant narrowing of bandwidth around a single peak of wavelength 610nm (Figure 11).

Example 12

Production of synthetic Photinus pyralis luciferase mutated

such that it has 214C/354K/357F

A synthetic luc gene was designed and assembled from oligonucleotide pairs using the synthesis strategy outlined above. The gene sequence was engineered to create a luciferase with the amino acids 214C, 354K and 357F.

Twenty-nine pairs of overlapping synthetic oligonucleotides were synthesised by Sigma-Genosys Ltd, purified by PAGE and ligated in three assemblies of approximately 550bp (IDRIS 1,2 & 3, Figure 13). Each assembly was then ligated separately into the vector pBSK(+) and the resulting constructs were used to transform *E. coli* XL1-Blue cells. Plasmid DNA was prepared from clones containing the assembled inserts and sequenced to confirm the fidelity of the ORFs. The presence of n-1 oligonucleotides (by-products of the oligosynthesis) in the assemblies complicated the build process. DNA sequencing identified a single correct assembly of IDRIS 2 and the PCR was used to correct one assembly of IDRIS 3 which contained a single base pair deletion at the 5' end of the construct. Assembly of the complete ORF was achieved by ligating a mixture of plasmids containing IDRIS 1 with IDRIS 2 and 3.

The ligated DNA was then used to transform *E. coli* XL1-Blue cells and clones expressing active enzyme were selected using an *in vivo* assay. Several clones were selected and sequenced to confirm the presence and fidelity of the synthetic *luc* gene having the sequence shown in Figure 14. The complete ORF was called IDRIS (FA).

- The synthetic gene was assembled into the vector pBSK(+) between the BamH I and Sal I sites in the polylinker. In this position the gene is not in frame with the alpha peptide and is a significant distance from the lac promoter. However, enough
- 5 luciferase is produced to enable preliminary characterisation of the enzyme. Crude cell free extracts of *E. coli* XL1-Blue cells expressing IDRIS (FA) were prepared, from overnight cultures, using the Promega lysis method.
- 10 The thermostability of the enzyme in the extract was then tested at 50°C over 20 minutes and compared with the thermostable mutant E354I+D357Y. The new codon optimised triple mutant was significantly more thermostable than the mutant E354I+D357Y (Figure 15).

Claims

1. A recombinant protein having luciferase activity and at least 60% similarity to a wild-type luciferase wherein in the
5 sequence of the enzyme, the amino acid residue corresponding to residue 357 in *Photinus pyralis* luciferase is mutated as compared to the corresponding wild-type luciferase, such that the luciferase enzyme is able to emit light at a different wavelength as compared to the corresponding wild-type
10 luciferase and/or has enhanced thermostability as compared to the corresponding wild-type luciferase.
2. A recombinant protein according to claim 1 wherein the said wild-type luciferase sequence is of luciferase from
15 *Photinus pyralis*, *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis*, *Hotaria paroula*, *Pyrophorus plagiophthalmus*, *Lampyrus noctiluca*, *Pyrocoelia nayako* or *Photinus pennsylvanica*.
- 20 3. A recombinant protein according to claim 2 wherein the wild type luciferase sequence is the sequence of an enzyme obtainable from *Photinus pyralis*, *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis* enzyme.
- 25 4. A recombinant protein according to claim 1 or claim 2 wherein said wild-type luciferase sequence is of luciferase from *Photinus pyralis*, *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis*, *Hotaria paroula*, *Pyrophorus plagiophthalmus*, *Lampyrus noctiluca* or *Pyrocoelia nayako* and the amino acid
30 residue corresponding to residue 357 in *Photinus pyralis* luciferase is other than aspartic acid or glutamic acid.
5. A recombinant protein according to claim 1 or claim 2 wherein said wild-type luciferase sequence is of luciferase
35 from *Photinus pennsylvanica* and the amino acid residue corresponding to residue 357 in *Photinus pyralis* luciferase is other than valine.

6. A recombinant protein according any one of the preceding claims wherein the amino acid residue corresponding to residue 357 in *Photinus pyralis* luciferase is other than aspartic acid, glutamic acid or valine.

5

7. A recombinant protein according any one of the preceding claims wherein the amino acid residue corresponding to residue 357 in *Photinus pyralis* luciferase is an uncharged polar amino acid.

10

8. A recombinant protein according to claim 7 wherein the amino acid residue corresponding to residue 357 in *Photinus pyralis* luciferase is tyrosine, phenylalanine or tryptophan.

15

9. A recombinant protein according to claim 8 wherein the amino acid residue corresponding to residue 357 in *Photinus pyralis* luciferase is tyrosine.

20

10. A protein according to any one of the preceding claims wherein the protein has at least 80% similarity to luciferase from *Photinus pyralis*, *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis*.

25

11. A protein according to any one of the preceding claims which has at least one of the following mutations as compared to wild type luciferase:

(a) the amino acid residue corresponding to amino acid 354 of the *Photinus pyralis* luciferase (356 in *Luciola* luciferase) is mutated;

30

(b) the amino acid residue corresponding to position 215 in *Photinus pyralis* luciferase or (217 in *Luciola* luciferase) is a different hydrophobic amino acid;

(c) the amino acid residue corresponding to residue 214 in *Photinus pyralis* luciferase or to residue 216 of *Luciola*

35

mingrelica, *Luciola cruciata* or *Luciola lateralis* luciferase;

- (d) the amino acid residue corresponding to residue 232 in *Photinus pyralis* luciferase or to residue 234 of *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis* luciferase;
- (e) amino acid residue corresponding to residue 295 in *Photinus*
5 *pyralis* luciferase or to residue 297 of *Luciola mingrelica*,
Luciola cruciata or *Luciola lateralis* luciferase;
- (f) amino acid residue corresponding to amino acid 14 of the
Photinus pyralis luciferase or to residue 16 of *Luciola*
mingrelica, *Luciola cruciata* or *Luciola lateralis*;
- 10 (g) amino acid residue corresponding to amino acid 35 of the
Photinus pyralis luciferase or to residue 37 of *Luciola*
mingrelica, *Luciola cruciata* or *Luciola lateralis*;
- (h) amino acid residue corresponding to amino acid residue 105
of the *Photinus pyralis* luciferase or to residue 106 of *Luciola*
15 *mingrelica*, *Luciola cruciata* or *Luciola lateralis*;
- (i) amino acid residue corresponding to amino acid residue 234
of the *Photinus pyralis* luciferase or to residue 236 of *Luciola*
mingrelica, *Luciola cruciata* or *Luciola lateralis*;
- (j) amino acid residue corresponding to amino acid residue 420
20 of the *Photinus pyralis* luciferase or to residue 422 of *Luciola*
mingrelica, *Luciola cruciata* or *Luciola lateralis*;
- (k) amino acid residue corresponding to amino acid residue 310
of the *Photinus pyralis* luciferase or to residue 312 of *Luciola*
mingrelica, *Luciola cruciata* or *Luciola lateralis*;
- 25 is different to the amino acid which appears in the
corresponding wild type sequence and wherein the luciferase
enzyme has increased thermostability as compared to an enzyme
having the amino acid of the corresponding wild-type luciferase
at this position.

30

12. A protein according to any one of the preceding claims
wherein the amino acid residue corresponding to amino acid 354
of the *Photinus pyralis* luciferase (356 in *Luciola* luciferase)
is mutated.

35

13. A protein according to claim 12 wherein the amino acid
residue corresponding to residue 214 in *Photinus pyralis*

luciferase or to residue 216 of *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis* luciferase is mutated to a different hydrophobic amino acid.

5 14. A nucleic acid which encodes a luciferase according to any one of the preceding claims.

15. A nucleic acid according to claim 14 which comprises a synthetic gene.

10

16. A nucleic acid according to claim 14 wherein the codon usage has been optimised for a particular expression host and/or unique restriction sites have been introduced.

15 17. A nucleic acid according to claim 14 or claim 15 which comprises nucleotides 9-1661 of SEQ ID NO 1, or a sequence which has at least 90% similarity thereto.

18. A vector comprising a nucleic acid according to any one of
20 claims 14 to 17.

19. A cell transformed with a vector according to claim 18.

20. A method of producing a protein according to any one of
25 claims 1 to 13, which method comprises culture of a cell according to claim 19.

21. The use of a protein according to any one of claims 1 to 13 in a bioluminescent assay.

30


22. A kit comprising a protein according to any one of claims 1 to 13.

23. A kit according to claim 22 which further comprises
35 luciferin.

24. An assay for determining the presence in a sample of CoA, which assay comprises adding to a sample suspected of

containing CoA, luciferase as claimed in any one of claims 1 to 11 above together with other reagents which are required to bring about a luciferase/luciferin reaction, measuring the wavelenght of light emitted from the sample and relating this
5 to the presence or absence of CoA.

25. An assay according to claim 24 for use in diagnosis of diabetes.



2/24

Fig.2(a).




Fig.2(b).





Fig.2(c).



3/24

Fig.2(d).




Fig.2(e).





Fig.2(f).



4/24

Fig.2(g).









Fig.2(h).






6/24

Fig.5.



7/24



8/24

Fig.7a.




Fig.7b.





Fig.7c.



9/24

Fig.8(a).




Fig.8(b).






Fig.8(c).




10/24

Fig.9.




11/24

Fig.10.



12/24

Fig.11(a).



13/24




Fig.12.





Fig.13.




16/24

Fig.14.(1/8)


17/24

Fig.14 (Cont). (2/8)




18/24

Fig.14 (Cont).(3/8)



19/24

Fig.14 (Cont).(4/8)



20/24

Fig.14 (Cont).(5/8)





Fig.14 (Cont).(6/8)

SUBSTITUTE SHEET (RULE 26)


22/24

Fig.14 (Cont). (7/8)



23/24


Fig.14 (Cont). (8/8)



24/24

Fig.15.

Inactivation of mutants E354I+D357Y and IDRIS
(FA) at 50C



SEQUENCE LISTING

<110> The Secretary of State for Defence

White, Peter J
 Willey, Tara L
 Price, Rachel L
 Murphy, Melanie J
 Squirrell, David

<120> Novel Enzyme

<130> DERA/IPD/P1247/WOD

<140>

<141>

<150> GB 9925161.3

<151> 1999-10-26

<150> GB 0016744.5

<151> 2000-07-10

<160> 13

<170> PatentIn Ver. 2.1

<210> 1

<211> 1661

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (3)..(1661)

<220>

<223> Description of Artificial Sequence: cDNA sequence
 of the synthetic luciferase gene

<400> 1

gg atc caa atg gaa gac gcc aaa aac atc aag aaa ggc ccg gcg cca	47
Ile Gln Met Glu Asp Ala Lys Asn Ile Lys Lys Gly Pro Ala Pro	
-1 1 5 10	
ttc tat cct ctg gag gat ggc acc gct ggc gag caa ctg cat aag gct	95
Phe Tyr Pro Leu Glu Asp Gly Thr Ala Gly Glu Gln Leu His Lys Ala	
15 20 25	
atg aag cgt tac gcc ctg gtt cct ggt aca att gct ttt aca gat gca	143
Met Lys Arg Tyr Ala Leu Val Pro Gly Thr Ile Ala Phe Thr Asp Ala	
30 35 40 45	
cat atc gag gtg aac atc acg tac gcg gaa tac ttc gaa atg tcc gtt	191
His Ile Glu Val Asn Ile Thr Tyr Ala Glu Tyr Phe Glu Met Ser Val	
50 55 60	
cgc ctg gca gaa gct atg aaa cgc tat ggt ctg aat aca aat cac cgt	239
Arg Leu Ala Glu Ala Met Lys Arg Tyr Gly Leu Asn Thr Asn His Arg	
65 70 75	

atc gtc gta tgc agt gaa aac tct ctt caa ttc ttt atg ccg gtg ctg	287
Ile Val Val Cys Ser Glu Asn Ser Leu Gln Phe Phe Met Pro Val Leu	
80 85 90	
ggc gcg ctt ttt atc ggt gtt gca gtt gcg ccg gcg aac gac att tat	335
Gly Ala Leu Phe Ile Gly Val Ala Val Ala Pro Ala Asn Asp Ile Tyr	
95 100 105	
aat gaa cgt gaa ctg ctt aac agt atg aac att tcg cag cct acc gta	383
Asn Glu Arg Glu Leu Leu Asn Ser Met Asn Ile Ser Gln Pro Thr Val	
110 115 120 125	
gtc ttt gtt tcc aaa aag ggc ctg caa aaa att ctc aac gtg caa aaa	431
Val Phe Val Ser Lys Lys Gly Leu Gln Lys Ile Leu Asn Val Gln Lys	
130 135 140	
aaa ctg cca att atc cag aaa att att atc atg gat tct aaa acg gat	479
Lys Leu Pro Ile Ile Gln Lys Ile Ile Ile Met Asp Ser Lys Thr Asp	
145 150 155	
tac cag ggc ttt cag tcg atg tac acg ttc gtc aca tct cat ctg cct	527
Tyr Gln Gly Phe Gln Ser Met Tyr Thr Phe Val Thr Ser His Leu Pro	
160 165 170	
ccg ggt ttt aat gaa tac gat ttt gta cca gag tcc ttt gat cgt gac	575
Pro Gly Phe Asn Glu Tyr Asp Phe Val Pro Glu Ser Phe Asp Arg Asp	
175 180 185	
aaa aca att gca ctg atc atg aat tcc tct ggc tct act ggt ctg cct	623
Lys Thr Ile Ala Leu Ile Met Asn Ser Ser Gly Ser Thr Gly Leu Pro	
190 195 200 205	
aag ggt gtg gcc ctt ccg cat cgt tgt gcc tgc gtc cgt ttc tcg cat	671
Lys Gly Val Ala Leu Pro His Arg Cys Ala Cys Val Arg Phe Ser His	
210 215 220	
gcc cgc gat cct att ttt ggt aac caa atc att ccg gat act gcg att	719
Ala Arg Asp Pro Ile Phe Gly Asn Gln Ile Ile Pro Asp Thr Ala Ile	
225 230 235	
ctg agt gtt gtt cca ttc cac cat ggt ttt ggc atg ttt act aca ctc	767
Leu Ser Val Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu	
240 245 250	
ggc tat ctg atc tgt ggc ttt cgt gtc gtc ctc atg tat cgc ttt gaa	815
Gly Tyr Leu Ile Cys Gly Phe Arg Val Val Leu Met Tyr Arg Phe Glu	
255 260 265	
gaa gag ctg ttt ctg cgc tcc ctg cag gat tac aaa att caa agt gcg	863
Glu Glu Leu Phe Leu Arg Ser Leu Gln Asp Tyr Lys Ile Gln Ser Ala	
270 275 280 285	
ctt ctg gtg cca acc ctg ttt tca ttc ttc gcc aaa agc act ctg att	911
Leu Leu Val Pro Thr Leu Phe Ser Phe Phe Ala Lys Ser Thr Leu Ile	
290 295 300	
gac aaa tac gat ctg tct aat ctt cac gaa att gct agc ggc ggt gca	959
Asp Lys Tyr Asp Leu Ser Asn Leu His Glu Ile Ala Ser Gly Gly Ala	
305 310 315	
cct ctt tcg aaa gaa gtc gga gaa gcg gtt gca aaa cgc ttc cat ctt	1007

Pro	Leu	Ser	Lys	Glu	Val	Gly	Glu	Ala	Val	Lys	Arg	Phe	His	Leu	
320						325			330						
cca	ggc	atc	cgt	caa	ggc	tat	ggg	ctc	act	gag	act	act	agt	gct	att
Pro	Gly	Ile	Arg	Gln	Gly	Tyr	Gly	Leu	Thr	Glu	Thr	Thr	Ser	Ala	Ile
335						340			345						
ctg	att	aca	ccg	aag	ggc	gat	ttc	aaa	ccg	ggc	gcg	gtc	ggg	aaa	gtg
Leu	Ile	Thr	Pro	Lys	Gly	Asp	Phe	Lys	Pro	Gly	Ala	Val	Gly	Lys	Val
350			355			360						365			
gta	cca	ttt	ttt	gaa	gcg	aag	gtt	gtg	gat	ctg	gat	acc	ggc	aaa	acg
Val	Pro	Phe	Phe	Glu	Ala	Lys	Val	Val	Asp	Leu	Asp	Thr	Gly	Lys	Thr
			370						375			380			
ctg	ggc	gtt	aat	cag	cgt	ggc	gaa	ctg	tgt	gtc	cgc	ggg	cct	atg	att
Leu	Gly	Val	Asn	Gln	Arg	Gly	Glu	Leu	Cys	Val	Arg	Gly	Pro	Met	Ile
			385			390						395			
atg	tcc	ggg	tat	gta	aac	aat	ccg	gaa	gcg	acc	aac	gcc	ctt	att	gac
Met	Ser	Gly	Tyr	Val	Asn	Asn	Pro	Glu	Ala	Thr	Asn	Ala	Leu	Ile	Asp
400						405						410			
aag	gat	ggc	tgg	ctg	cat	tct	ggc	gac	atc	gct	tac	tgg	gac	gaa	gac
Lys	Asp	Gly	Trp	Leu	His	Ser	Gly	Asp	Ile	Ala	Tyr	Trp	Asp	Glu	Asp
415						420						425			
gaa	cac	ttc	ttc	atc	gtt	gac	cgc	ctg	aag	tct	ctc	att	aaa	tac	aaa
Glu	His	Phe	Phe	Ile	Val	Asp	Arg	Leu	Lys	Ser	Leu	Ile	Lys	Tyr	Lys
430			435						440			445			
ggc	tat	cag	gtg	gcc	cca	gct	gaa	ctg	gaa	tcg	atc	ctc	ctg	caa	cac
Gly	Tyr	Gln	Val	Ala	Pro	Ala	Glu	Leu	Glu	Ser	Ile	Leu	Leu	Gln	His
			450						455			460			
cca	aac	atc	ttc	gac	gcg	ggc	gtg	gca	ggg	ctt	ccg	gac	gat	gac	gcc
Pro	Asn	Ile	Phe	Asp	Ala	Gly	Val	Ala	Gly	Leu	Pro	Asp	Asp	Asp	Ala
			465			470						475			
ggg	gaa	ctt	ccg	gcc	gcc	gtt	gtt	gtt	ctc	gag	cac	ggg	aag	acg	atg
Gly	Glu	Leu	Pro	Ala	Ala	Val	Val	Val	Leu	Glu	His	Gly	Lys	Thr	Met
480						485						490			
acg	gaa	aaa	gag	atc	gtg	gat	tac	gtc	gcc	agt	caa	gta	aca	acc	gcg
Thr	Glu	Lys	Glu	Ile	Val	Asp	Tyr	Val	Ala	Ser	Gln	Val	Thr	Thr	Ala
495						500						505			
aaa	aag	ctg	cgc	ggg	ggc	gtt	gtg	ttt	gtg	gac	gaa	gta	ccg	aaa	ggg
Lys	Lys	Leu	Arg	Gly	Gly	Val	Val	Phe	Val	Asp	Glu	Val	Pro	Lys	Gly
510			515						520			525			
ctt	acc	ggc	aaa	ctc	gac	gca	cgt	aaa	atc	cgc	gag	atc	ctc	att	aag
Leu	Thr	Gly	Lys	Leu	Asp	Ala	Arg	Lys	Ile	Arg	Glu	Ile	Leu	Ile	Lys
			530						535			540			
gcc	aag	aag	ggc	ggg	aag	tcc	aag	ctt	taa						
Ala	Lys	Lys	Gly	Gly	Lys	Ser	Lys	Leu							
			545			550									
															1055
															1103
															1151

<210> 2
 <211> 552
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Encoded amino acid
 sequence of the cDNA sequence of synthetic
 luciferase gene

<400> 2

Ile	Gln	Met	Glu	Asp	Ala	Lys	Asn	Ile	Lys	Lys	Gly	Pro	Ala	Pro	Phe
-1	1					5					10				
Tyr	Pro	Leu	Glu	Asp	Gly	Thr	Ala	Gly	Glu	Gln	Leu	His	Lys	Ala	Met
15					20					25					30
Lys	Arg	Tyr	Ala	Leu	Val	Pro	Gly	Thr	Ile	Ala	Phe	Thr	Asp	Ala	His
				35					40					45	
Ile	Glu	Val	Asn	Ile	Thr	Tyr	Ala	Glu	Tyr	Phe	Glu	Met	Ser	Val	Arg
			50					55				60			
Leu	Ala	Glu	Ala	Met	Lys	Arg	Tyr	Gly	Leu	Asn	Thr	Asn	His	Arg	Ile
		65					70					75			
Val	Val	Cys	Ser	Glu	Asn	Ser	Leu	Gln	Phe	Phe	Met	Pro	Val	Leu	Gly
	80					85					90				
Ala	Leu	Phe	Ile	Gly	Val	Ala	Val	Ala	Pro	Ala	Asn	Asp	Ile	Tyr	Asn
95					100					105					110
Glu	Arg	Glu	Leu	Leu	Asn	Ser	Met	Asn	Ile	Ser	Gln	Pro	Thr	Val	Val
				115					120					125	
Phe	Val	Ser	Lys	Lys	Gly	Leu	Gln	Lys	Ile	Leu	Asn	Val	Gln	Lys	Lys
			130					135					140		
Leu	Pro	Ile	Ile	Gln	Lys	Ile	Ile	Ile	Met	Asp	Ser	Lys	Thr	Asp	Tyr
		145					150					155			
Gln	Gly	Phe	Gln	Ser	Met	Tyr	Thr	Phe	Val	Thr	Ser	His	Leu	Pro	Pro
160					165						170				
Gly	Phe	Asn	Glu	Tyr	Asp	Phe	Val	Pro	Glu	Ser	Phe	Asp	Arg	Asp	Lys
175					180					185					190
Thr	Ile	Ala	Leu	Ile	Met	Asn	Ser	Ser	Gly	Ser	Thr	Gly	Leu	Pro	Lys
				195					200					205	
Gly	Val	Ala	Leu	Pro	His	Arg	Cys	Ala	Cys	Val	Arg	Phe	Ser	His	Ala
			210					215					220		
Arg	Asp	Pro	Ile	Phe	Gly	Asn	Gln	Ile	Ile	Pro	Asp	Thr	Ala	Ile	Leu
		225					230					235			
Ser	Val	Val	Pro	Phe	His	His	Gly	Phe	Gly	Met	Phe	Thr	Thr	Leu	Gly
	240					245					250				
Tyr	Leu	Ile	Cys	Gly	Phe	Arg	Val	Val	Leu	Met	Tyr	Arg	Phe	Glu	Glu
255					260					265					270
Glu	Leu	Phe	Leu	Arg	Ser	Leu	Gln	Asp	Tyr	Lys	Ile	Gln	Ser	Ala	Leu
				275					280					285	
Leu	Val	Pro	Thr	Leu	Phe	Ser	Phe	Phe	Ala	Lys	Ser	Thr	Leu	Ile	Asp
			290					295					300		
Lys	Tyr	Asp	Leu	Ser	Asn	Leu	His	Glu	Ile	Ala	Ser	Gly	Gly	Ala	Pro
		305					310					315			
Leu	Ser	Lys	Glu	Val	Gly	Glu	Ala	Val	Ala	Lys	Arg	Phe	His	Leu	Pro
		320				325					330				
Gly	Ile	Arg	Gln	Gly	Tyr	Gly	Leu	Thr	Glu	Thr	Thr	Ser	Ala	Ile	Leu
335					340					345					350
Ile	Thr	Pro	Lys	Gly	Asp	Phe	Lys	Pro	Gly	Ala	Val	Gly	Lys	Val	Val
			355						360					365	
Pro	Phe	Phe	Glu	Ala	Lys	Val	Val	Asp	Leu	Asp	Thr	Gly	Lys	Thr	Leu
			370					375					380		
Gly	Val	Asn	Gln	Arg	Gly	Glu	Leu	Cys	Val	Arg	Gly	Pro	Met	Ile	Met
		385					390					395			

Ser Gly Tyr Val Asn Asn Pro Glu Ala Thr Asn Ala Leu Ile Asp Lys
 400 405 410
 Asp Gly Trp Leu His Ser Gly Asp Ile Ala Tyr Trp Asp Glu Asp Glu
 415 420 425 430
 His Phe Phe Ile Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly
 435 440 445
 Tyr Gln Val Ala Pro Ala Glu Leu Glu Ser Ile Leu Leu Gln His Pro
 450 455 460
 Asn Ile Phe Asp Ala Gly Val Ala Gly Leu Pro Asp Asp Asp Ala Gly
 465 470 475
 Glu Leu Pro Ala Ala Val Val Val Leu Glu His Gly Lys Thr Met Thr
 480 485 490
 Glu Lys Glu Ile Val Asp Tyr Val Ala Ser Gln Val Thr Thr Ala Lys
 495 500 505 510
 Lys Leu Arg Gly Gly Val Val Phe Val Asp Glu Val Pro Lys Gly Leu
 515 520 525
 Thr Gly Lys Leu Asp Ala Arg Lys Ile Arg Glu Ile Leu Ile Lys Ala
 530 535 540
 Lys Lys Gly Gly Lys Ser Lys Leu
 545 550

<210> 3
 <211> 1661
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: cDNA sequence
 of synthetic luciferase gene

<400> 3
 ttaaagcttg gacttacgc ccttcttggc cttaatgagg atctcgcgga ttttacgtgc 60
 gtcgagtttg ccggttaagac ctttcggttac ttctgtccaca aacacaacgc caccgcgcag 120
 ctttttcgcg gttgttactt gactggcgac gtaatccacg atctcttttt ccgtcatcgt 180
 cttaccgtgc tcgagaacaa caacggcggc cggaagtcca ccggcgatcat cgtccggaag 240
 acctgccacg cccgcgtcga agatgttttg gtgttgacagg aggatcgatt ccagttcagc 300
 tggggccacc tgatagcctt tgtatttaat gagagacttc aggcgggtcaa cgatgaagaa 360
 gtgttcgtct tcgtccagct aagcgatgtc gccagaatgc agccagccat ccttgtcaat 420
 aaggggcttg gtcgcttcgc gattgtttac ataaccggac ataatcatag gaccgcggac 480
 acacagttcg ccacgctgat taacgcccag cgttttgccg gtatccagat ccacaacctt 540
 cgcttcaaaa aatggtacca ctttacgcac cgcgcccggt ttgaaatcgc ccttcggtgt 600
 aatcagaata gcactagtag tctcagttag accatagcct tgacggatgc ctggaagatg 660
 gaagcgtttt gcaaccgctt ctccgacttc ttctgaaaga ggtgcaccgc cgctagcaat 720
 ttcgtgaaga ttagacagat cgtatttgtc aatcagagtgc cttttggcga agaataaaaa 780
 cagggttggc accagaagcg cactttgaat tttgtaatcc tgcagggagc gcagaaacag 840
 ctcttcttca aagcgataca tgaggacgac acgaaagcca cagatcagat agccgagtgt 900
 agtaaacatg ccaaaaccat ggtggaatgg aacaacactc agaatcgag tatccggaat 960
 gatttggtta ccaaaaatag gatcgcgggc atgcgagaaa cggacgcagg cacaacgatg 1020
 cggaagggcc acacccttag gcagaccagt agagccagag gaattcatga tcagtgaat 1080
 tgttttgtca cgatcaaagg actctggtac aaaatcgtat tcattaaaac ccggaggcag 1140
 atgagatgtg acgaacgtgt acatcgactg aaagccctgg taatccgttt tagaatccat 1200
 gataataatt ttctggataa ttggcagttt tttttgcacg ttgagaattt tttgcaggcc 1260
 ctttttgtaa acaaagacta cggtaggctg cgaaatgttc atactgttaa gcagttcacg 1320
 ttcattataa atgtcgttcg ccggcgcaac tgcaacaccg ataaaaagcg cgcccagcac 1380
 cggcataaag aattgaagag agttttcact gcatacgacg atacggtgat ttgtattcag 1440
 accatagcgt ttcatagctt ctgccaggcg aacggacatt tcgaagtatt ccgcgtacgt 1500
 gatgttcacc tcgatattgt catctgtaaa agcaattgta ccaggaacca gggcgtaacg 1560
 cttcatagcc ttatgcagtt gctcgccagc ggtgccatcc tccagaggat agaattggcg 1620
 cgggcctttc ttgatgtttt tggcgtcttc catttgatc c 1661

<210> 4
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 4
cacccgaggg ggattataaa ccgggcgcgg 30

<210> 5
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 5
cacccgaggg ggatvycaaa ccgggcgcgg tcgg 34

<210> 6
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 6
cacccgaggg ggattdsaaa ccgggcgcgg tcgg 34

<210> 7
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 7
cacccgaggg ggatmrsaaa ccgggcgcgg tcgg 34

<210> 8
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:

Oligonucleotide

<400> 8
gggctcactg agactactag tgctattatg attacaccg 40

<210> 9
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 9
cgggtgtaat cagaatagca ctagtagtct cagtgaagccc 40

<210> 10
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 10
ggcgcggtcg gtaaagtggg accatTTTTT gaagcg 36

<210> 11
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 11
cgcttcaaaa aatggtacca ctttaccgac cgcgcc 36

<210> 12
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (24)..(25)
<223> n=a or g or c or t

<220>
<221> misc_feature
<222> (33)..(34)
<223> n=a or g or c or t

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 12

ctagtgttat tctgattaca ccnnsgggg atnnsaaacc gggcgcggtc ggtaaagtgg 60
ta 62

<210> 13

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

<221> misc_feature

<222> (26)..(27)

<223> n=a or g or c or t

<220>

<221> misc_feature

<222> (35)..(36)

<223> n=a or g or c or t

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 13

cactttaccg accgcgcccg gtttsnnatc cccsnngggt gtaatcagaa tagca 55